Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Genomic Health (GHDX) Q4 Earnings & Revenues Miss Estimates

Genomic Health's (GHDX) escalating operating expenses dent bottom line in Q4.

    Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects

    Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.

      Pacific Biosciences Unveils New Version of Sequel Software

      Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.

        Here's Why You Should Add Amedisys (AMED) to Your Portfolio

        Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.

          Quest Diagnostics Long-Term View Solid, Reimbursement a Woe

          Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.

            CryoLife (CRY) Beats Earnings and Revenue Estimates in Q4

            CryoLife (CRY) gains on growth in all the product lines along with a strong performance in all the geographies in Q4.

              NuVasive Gains From International Business Amid Pricing Woes

              Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors

                Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit

                Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.

                  Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio

                  Abbott (ABT) adopts initiatives to strengthen the Structural Heart business within the Medical Device segment.

                    Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed

                    Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.

                      Henry Schien to Distribute Grifols Product in United States

                      We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

                        Boston Scientific Acquires EMcision, Boosts Endoscopy Unit

                        Boston Scientific (BSX) adopts initiatives to strengthen the Endoscopy business.

                          Abaxis Banks on Strong Veterinary Business Amid Margin Woes

                          Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.

                            Integra LifeSciences Banks on CSS Segment, Competition Rife

                            Integra LifeSciences (IART) rides high on strength in the Codman Specialty Surgical segment.

                              Here's Why Teleflex Has Been Losing Ground Since Q4 Earnings

                              Teleflex's (TFX) contracted Q4 adjusted operating margin is discouraging.

                                Bio-Rad (BIO) Q4 Earnings Improve Y/Y, Revenues Top Mark

                                Bio-Rad's (BIO) strong sales in Q4 ride high on a robust performance at Life Science product lines.

                                  Hologic's Alliance With Philips to Boost Breast Health Unit

                                  Hologic (HOLX) is consistently trying to fortify its Breast Health segment.

                                    OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down

                                    OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.

                                      Medtronic's Guardian Sensor 3 With MiniMed 670G Wins FDA Nod

                                      Medtronic (MDT) advances with initiatives to boost the performance of its MiniMed portfolio.

                                        DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q4

                                        Strong performance at Dental & Healthcare Consumables segment drives DENTSPLY's (XRAY) Q4 sales.

                                          Patterson Companies (PDCO) Misses on Q3 Earnings, Cuts View

                                          Lower sales and gross-margin compression mars Patterson Companies' (PDCO) results in Q3.

                                            Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive

                                            Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.

                                              DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4

                                              DexCom (DXCM) rides high on strength in all segments in Q4.

                                                Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates

                                                Amedisys (AMED) registers strong growth across all segments in Q4.

                                                  Express Scripts (ESRX) Q4 Earnings Top, Long-Term View Solid

                                                  Express Scripts' (ESRX) fourth-quarter 2017 results benefit from rise in patient claims and strong customer retention.